← Surfer · The Kit · Coach hub
Coach — AREDS3 (RPE engine support vs. interference)
The AREDS eye vitamins are among the best-tested supplements in medicine, for one specific group of people. This essay reads each part of the newest formula against the mitochondrial engine of the retina, and asks which parts help that engine and which may work against it.
Safety first
The extended report opens with a caution: "This document presents a metabolic hypothesis integrating available clinical trial data from the Age-Related Eye Disease Studies (AREDS and AREDS2) with mechanistic biochemistry and the EnSurf framework of mitochondrial optimization. It is not medical advice, does not constitute a recommendation for or against any supplement, and is not a substitute for individualized clinical judgment. The original AREDS and AREDS2 trials established efficacy for the tested formulas in specific high-risk populations with intermediate age-related macular degeneration (AMD). AREDS3 is a commercial product formulation that has not been tested in a new randomized outcome trial. Individual responses vary. Consult a qualified physician before making changes to supplementation, particularly in the presence of diagnosed AMD or other medical conditions."
One caution applies to an older formula: "Smokers and former smokers should avoid beta-carotene formulas (AREDS2 found more lung cancers in former smokers taking beta-carotene); AREDS2 and AREDS3 do not contain it."
Two clinical lines frame everything below. Without intermediate AMD, the formula, zinc included, is not indicated. And wherever a lower-zinc option is discussed, zinc stays paired with copper. Choosing, starting, or changing an eye supplement, especially with diagnosed AMD, belongs with your eye doctor. Any amounts named here are the amounts in the tested and commercial formulas, given as information, not as a dose for anyone.
AMD as a dashboard of engine failure
The retinal pigment epithelium, the single layer of cells behind the photoreceptors, faces some of the highest energy demands in the body. It runs on mitochondrial respiration while it continuously supports the turnover of photoreceptor outer segments, digesting their worn tips. Over decades, insults accumulate: light-driven oxidative stress, oxidized lipids, activation of the complement system, and an age-related decline in mitochondrial cleanup and in the recycling of NAD+, the cell's key energy carrier. The result, in the hypothesis behind this essay, is mitochondrial dysfunction, lysosomes that lose their acidity, reactive oxygen beyond the helpful range, and failing clearance. The clinical signs of AMD, drusen, geographic atrophy, and abnormal new vessels, are the visible readout of that engine failure.
AREDS and AREDS2 showed that a multi-part formula can slow progression in people who already have intermediate disease, or advanced disease in one eye. AREDS3 keeps the core nutrients, lowers the zinc, and adds a group of B vitamins. The question this essay asks is not whether the trials were right. It is how each part of the formula fits with the work of a mitochondrial engine, and with the strength training that this site treats as one of the main ways to rebuild it.
What is in the formula
As the report describes it, the amounts are these, listed so that a conversation with an eye doctor can start from the label. Zinc was lowered from 80 milligrams in the original formula to 25 in AREDS3; the AREDS2 secondary randomization found no significant difference in progression between the two amounts, and the lower one is better tolerated. Copper, 2 milligrams as cupric oxide, is there only to offset the copper deficiency that zinc can cause. Lutein, 10 milligrams, and zeaxanthin, 2 milligrams, replaced beta-carotene in AREDS2. The antioxidant fraction is 500 milligrams of vitamin C and about 180 milligrams, or 400 IU, of synthetic vitamin E. AREDS3 adds 32 milligrams of nicotinamide, a form of vitamin B3, with other B vitamins.
Zinc with copper
Zinc fits the engine best. It was the stronger single component in the original AREDS factorial design, though only the full combination was significant across everyone enrolled. It concentrates in the retinal pigment epithelium and the choroid beneath it, and it is a working part of several of the cell's own antioxidant enzymes. It supports glutathione synthesis and can switch on the cell's defense program. In cell and animal studies it helps keep lysosomes acidic enough to digest photoreceptor debris and clear the toxic pigment by-product A2E, preserves mitochondrial ATP production under oxidative load, and modulates complement. Those actions address core failures of the engine rather than simply mopping up free radicals.
Copper is a countermeasure. High-dose zinc competes with copper for absorption in the gut and induces a binding protein that traps copper, so prolonged high zinc can cause copper deficiency, with possible anemia and nerve effects. Copper is not in the formula for any direct eye benefit; it is there to keep copper balance when zinc is supplemented at the tested amounts. In the original trials, laboratory measures showed no copper-deficiency anemia with the combination, though self-reported anemia was slightly higher with zinc. That is why the two are discussed together, always.
The carotenoids
Lutein and zeaxanthin are supportive. They collect in the macula as macular pigment and filter short-wavelength blue light, which reduces light-driven reactive oxygen in the outer retina. In cell and animal studies they also act as antioxidants within membranes and limit the phototoxicity of retinal debris. In a mouse model of mitochondrial oxidative stress in the pigment epithelium, daily zeaxanthin preserved the structure of those cells, kept their mitochondria more intact, improved a measure of their electrical function, and raised antioxidant genes (Biswal and colleagues, PLOS One, 2018). That points to an engine-level contribution, not only an optical one.
Nicotinamide, a small liability
The B3 question is subtler. The cell can make NAD+ by two main routes. One starts from nicotinic acid and, in the hypothesis, raises NAD+ without producing nicotinamide along the way. The other recycles nicotinamide through a salvage pathway. Nicotinamide also inhibits the sirtuins, enzymes that depend on NAD+, when its concentration is high enough. The 32 milligrams in AREDS3 is modest compared with the levels shown to suppress sirtuins in the laboratory, but it is not zero. The report therefore favors the nicotinic acid route, discussed in the essay on NAD precursors, as physician-guided; this essay gives no nicotinic acid amount. It also argues that adding other precursors on top of good food, light, and training is unlikely to add much, because the recycling pathway is already fed from within.
Vitamins C and E, the least aligned
The antioxidant fraction fits worst. In the original AREDS, vitamins C and E were tested only alongside beta-carotene, and antioxidants alone produced a weaker, often non-significant reduction in progression compared with zinc or the full combination. In the hypothesis, high-dose vitamin C and E can also blunt the reactive oxygen signals that working muscle produces during exercise, signals that tell cells to build new mitochondria, switch on their own antioxidant enzymes, and grow. A program that uses strength training to generate those pulses is the setting in which this fraction is most likely to work against the intended adaptation. Synthetic vitamin E is also retained less efficiently by the liver than the natural form, so more of the dose is a less useful version of the molecule.
The report discusses separation in time as a possible mitigation. Exercise-driven reactive oxygen peaks during and in the hours just after a session, so intake that falls after that window would, in the hypothesis, interfere less than intake during it. In the report's words, it "does not eliminate all risk of chronic redox dampening." When intermediate AMD is present, whether and how to use the formula, and when, belongs with the treating eye doctor. The training week the session belongs to is explained in the extended report on strength.
How it fits
The overall reading is a trade-off for one group of people. AREDS3 is a disease-stage intervention tested in people who already show intermediate AMD. Its zinc, with copper, maps reasonably onto engine support. Its carotenoids support macular pigment and mitochondrial resilience. Its nicotinamide is a small liability, and its high-dose synthetic antioxidants are the least compatible element. For someone without intermediate AMD, the formula is not indicated, zinc included, and the cleaner path is the food, daily rhythm, and training that build the engine from within. For someone who already has intermediate disease, the report frames a lower-zinc formula, with copper, as a reasonable trade-off: it keeps the component with the strongest single-ingredient trial signal. That choice belongs with the treating eye doctor. In both cases, the primary repair is the way of living, and the formula is at best a secondary, stage-specific adjunct. The trials remain the evidence for the formula in the people they studied. The grading of each part as support or interference is the hypothesis, and it would need its own trial to become more than that.
The wider picture of the eye is in the eye essay. Related essays look at PQQ and at acetyl-L-carnitine, including its retina and optic nerve note.
For the full argument, read the extended report on AREDS3. The short version is in the lessons. Talk with your own physician before changing medications or supplements.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.
See the notice at the top of this page. Working hypothesis, not medical advice and not a dosing recommendation. Not a self-treatment guide. Consult a qualified physician before making changes to supplementation, particularly in the presence of diagnosed AMD or other medical conditions.